Table 1 Prevalence of autoantibodies in Mexican patients with PM/DM
PM/DM | PM | DM | Adult-onset DM | Juvenile- onset DM | |
|---|---|---|---|---|---|
Number | 95 | 29 | 66 | 61 | 5 |
Age | 44.4 | 48.4 | 42.8 | 45.3 | 18.2 |
Mean ± SD | ± 14.2 | ± 10.2 | ± 15.3 | ± 14.4 | ± 9.7 |
Male | 33% | 41% | 29% | 28% | 40% |
Autoantibodies | |||||
Jo-1 | 4% | 7% | 3% | 3% | 0% |
Mi-2 (95% CI) | 35% | 10%a (2.1 to 26.5) | 45%a (33.1 to 58.2) | 45% | 40% |
p155/140 (95% CI) | 11% | 0%b (0.0 to 11.9) | 15%b (7.5 to 26.1) | 16% | 0% |
MJ/NXP-2 | 3% | 0% | 5% | 3% | 20% |
SAE | 2% | 0% | 3% | 3% | 0% |
SRP | 3% | 7% | 2% | 2% | 0% |
PM-Scl | 3% | 0% | 5% | 5% | 0% |
U1RNP | 3% | 7% | 2% | 2% | 0% |
Negative | 36% | 69%c | 21%c | 20% | 40% |
Su/Ago2 | 8% | 7% | 9% | 10% | 0% |
Ro60 | 13% | 7% | 15% | 15% | 20% |
Ro52d | 21% | 16% | 22% | 24% | 0% |